Drug Patents owned by Viiv Hlthcare

1. List of Apretude drug patents

APRETUDE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

APRETUDE family patents

32

United States

13

Japan

12

European Union

9

Spain

7

Hungary

7

Slovenia

7

Denmark

6

Portugal

6

Korea, Republic of

6

Poland

5

Norway

5

Lithuania

4

Mexico

4

Hong Kong

4

Cyprus

4

Israel

3

Brazil

3

China

3

Taiwan, Province of China

3

EA

3

South Africa

3

Canada

3

Australia

2

Morocco

2

Luxembourg

2

Ukraine

2

Netherlands

1

Croatia

1

San Marino

1

New Zealand

1

Philippines

1

Austria

1

ME

1

Viet Nam

1

Chile

1

RS

2. List of Cabenuva Kit drug patents

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(21 days from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatment of hiv infection in adults; Treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

67

United States

35

European Union

23

Japan

21

Norway

21

Hungary

16

Spain

14

Korea, Republic of

13

Slovenia

13

Denmark

12

Lithuania

12

Australia

11

Portugal

11

China

11

Poland

10

Brazil

9

Mexico

9

Hong Kong

9

Israel

8

Croatia

8

Taiwan, Province of China

8

EA

8

Canada

8

Cyprus

7

Luxembourg

6

New Zealand

6

South Africa

6

Ukraine

5

AP

4

Austria

4

Argentina

3

Belgium

3

RS

3

Netherlands

2

Singapore

2

Malaysia

2

Jordan

2

Costa Rica

2

Morocco

2

Nicaragua

2

ME

2

Chile

1

Germany

1

Uruguay

1

Panama

1

San Marino

1

Egypt

1

Philippines

1

Peru

1

Viet Nam

1

OA

3. List of Dovato drug patents

DOVATO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 6, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's patent expiration?
More Information on Dosage

DOVATO family patents

48

United States

22

Japan

18

European Union

12

Spain

11

Korea, Republic of

10

Hungary

10

Australia

9

Mexico

9

Slovenia

9

Denmark

8

Portugal

8

Hong Kong

8

Canada

8

Israel

8

Poland

7

Norway

7

Lithuania

6

EA

6

Cyprus

5

New Zealand

5

China

4

Singapore

4

Brazil

3

Croatia

3

Philippines

3

Morocco

3

Taiwan, Province of China

3

South Africa

3

Luxembourg

3

RS

2

Russia

2

Dominican Republic

2

Peru

2

ME

2

Ukraine

2

Netherlands

1

Turkey

1

Malaysia

1

Costa Rica

1

San Marino

1

Colombia

1

AP

1

Austria

1

Tunisia

1

Viet Nam

1

Chile

1

Ecuador

4. List of Juluca drug patents

JULUCA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(21 days from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 VIIV HLTHCARE Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(7 months ago)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's patent expiration?
More Information on Dosage

JULUCA family patents

78

United States

37

European Union

31

Japan

23

Norway

23

Hungary

18

Spain

18

Korea, Republic of

18

Australia

14

Slovenia

14

Denmark

13

Mexico

13

Hong Kong

13

Lithuania

12

Portugal

12

China

12

Canada

12

Israel

12

Poland

10

Brazil

10

EA

9

Croatia

9

New Zealand

9

Cyprus

8

Luxembourg

7

Taiwan, Province of China

6

South Africa

5

Singapore

5

AP

5

Ukraine

4

Austria

4

RS

3

Malaysia

3

Costa Rica

3

Philippines

3

Argentina

3

Morocco

3

Belgium

3

ME

3

Netherlands

2

Russia

2

Dominican Republic

2

Peru

2

Nicaragua

1

Turkey

1

Germany

1

Panama

1

Jordan

1

San Marino

1

Colombia

1

Egypt

1

Tunisia

1

Viet Nam

1

OA

1

Chile

1

Ecuador

5. List of Rukobia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(1 year, 11 months from now)

US7745625 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(1 year, 11 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 2, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 2024-07-02

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RUKOBIA family patents

16

United States

2

New Zealand

2

China

2

Hong Kong

2

Israel

1

Portugal

1

Germany

1

Malaysia

1

Russia

1

Spain

1

Brazil

1

Croatia

1

Norway

1

Austria

1

Argentina

1

Peru

1

Taiwan, Province of China

1

Korea, Republic of

1

South Africa

1

Japan

1

Canada

1

Cyprus

1

Slovenia

1

Ukraine

1

Georgia

1

Poland

1

Australia

1

RS

1

Denmark

1

European Union

6. List of Selzentry drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(1 year, 1 month ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(3 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(2 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 30, 2023
Pediatric Exclusivity (PED) Apr 30, 2024

Drugs and Companies using MARAVIROC ingredient

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's patent expiration?
More Information on Dosage

SELZENTRY family patents

5

United States

3

Germany

3

Malaysia

3

Spain

3

Norway

3

China

3

Hong Kong

3

European Union

2

Portugal

2

United Kingdom

2

Austria

2

Argentina

2

Korea, Republic of

2

EA

2

Japan

2

Slovenia

2

Australia

2

Denmark

1

Turkey

1

Uruguay

1

Panama

1

Guatemala

1

Brazil

1

Croatia

1

Costa Rica

1

IB

1

New Zealand

1

AP

1

Egypt

1

Estonia

1

Mexico

1

Morocco

1

Peru

1

Taiwan, Province of China

1

Tunisia

1

South Africa

1

Slovakia

1

Lithuania

1

Canada

1

Cyprus

1

ME

1

Luxembourg

1

Czech Republic

1

Iceland

1

Israel

1

Ukraine

1

OA

1

Bulgaria

1

Georgia

1

Poland

1

Yugoslavia

1

RS

1

Algeria

1

Ecuador

1

Cuba

1

Netherlands

1

Hungary

7. List of Tivicay drug patents

TIVICAY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 August, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TIVICAY before it's patent expiration?
More Information on Dosage

TIVICAY family patents

33

United States

15

Japan

13

European Union

9

Spain

7

Korea, Republic of

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Mexico

5

Hong Kong

5

Poland

4

Lithuania

4

Canada

4

Australia

3

Brazil

3

China

3

Taiwan, Province of China

3

Cyprus

3

Israel

2

Russia

2

Morocco

2

EA

2

South Africa

2

Luxembourg

2

Netherlands

1

Singapore

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

8. List of Tivicay Pd drug patents

TIVICAY PD's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TIVICAY PD before it's patent expiration?
More Information on Dosage

TIVICAY PD family patents

33

United States

15

Japan

13

European Union

9

Spain

7

Korea, Republic of

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Mexico

5

Hong Kong

5

Poland

4

Lithuania

4

Canada

4

Australia

3

Brazil

3

China

3

Taiwan, Province of China

3

Cyprus

3

Israel

2

Russia

2

Morocco

2

EA

2

South Africa

2

Luxembourg

2

Netherlands

1

Singapore

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

9. List of Triumeq drug patents

TRIUMEQ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 22 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TRIUMEQ before it's patent expiration?
More Information on Dosage

TRIUMEQ family patents

33

United States

15

Japan

13

European Union

9

Spain

7

Korea, Republic of

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Mexico

5

Hong Kong

5

Poland

4

Lithuania

4

Canada

4

Australia

3

Brazil

3

China

3

Taiwan, Province of China

3

Cyprus

3

Israel

2

Russia

2

Morocco

2

EA

2

South Africa

2

Luxembourg

2

Netherlands

1

Singapore

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

10. List of Triumeq Pd drug patents

TRIUMEQ PD's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

TRIUMEQ PD family patents

33

United States

15

Japan

13

European Union

9

Spain

7

Korea, Republic of

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Mexico

5

Hong Kong

5

Poland

4

Lithuania

4

Canada

4

Australia

3

Brazil

3

China

3

Taiwan, Province of China

3

Cyprus

3

Israel

2

Russia

2

Morocco

2

EA

2

South Africa

2

Luxembourg

2

Netherlands

1

Singapore

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

11. List of Vocabria drug patents

VOCABRIA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
M (M) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR SODIUM ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 in an adult in combination with rilpivirine

Dosage: TABLET;ORAL

More Information on Dosage

VOCABRIA family patents

26

United States

12

Japan

11

European Union

8

Spain

6

Hungary

6

Slovenia

6

Denmark

5

Portugal

5

Norway

5

Korea, Republic of

5

Poland

4

Hong Kong

4

Lithuania

3

Mexico

3

Cyprus

3

Israel

2

Brazil

2

Morocco

2

China

2

Taiwan, Province of China

2

EA

2

South Africa

2

Canada

2

Luxembourg

2

Australia

2

Netherlands

1

New Zealand

1

Philippines

1

Austria

1

Ukraine

1

Viet Nam

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in